We are delighted to announce further success in our collaboration with AstraZeneca. Using BenevolentAI’s AI-drug discovery platform, a novel target for systemic lupus erythematosus (SLE) has been identified. 🎯 The target has been experimentally validated by AstraZeneca and added to its discovery portfolio. Following the heart failure milestone, it’s the second target to be selected this year from our extended collaboration. 📣 Prof Maria Belvisi, SVP and Head of Research and Early Development Respiratory and Immunology at AstraZeneca said: “By combining our immunology disease area expertise and BenevolentAI’s AI-driven discovery platform, we are increasing our ability to identify new targets based on patient insights, complementing our portfolio of potential treatments for this debilitating disease.” SLE, or lupus, can cause inflammation, pain and damage – often affecting the organs and joints in severe cases. Extreme fatigue and cognitive issues are also common, along with comorbidities including cardiovascular disease. Read more here: https://lnkd.in/e2mq8haw
Congratulations, Will and Team
Great news
Congratulations Joerg Moeller, M.D. and to the teams involved, the future is here and #AI is making a difference! Amazing to think about what is yet to come if this gets scaled further!!